Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 6/27/24 → 6/27/26 |
Funding
- Regeneron Pharmaceuticals: $74,350.00
23-MYEL-21-RG: An Open-Label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti-BCMA x Anti-CD3 Bispecific Antibody) Vs. The Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory Mulitple Myeloma (
- Monohan, Gregory (PI)